Kite Pharma Overview

  • Founded
  • 2009
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 200
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $12B
Latest Deal Amount

Kite Pharma General Information

Description

Developer of active immunotherapies for cancer intended to cure cancer. The company is engaged in developing engineered cell therapies that express either a chimeric antigen receptor (CAR) or a T cell receptor (TCR), depending on the type of cancer. It's dual platform has the potential to change the paradigm of cancer therapy and address both hematological and solid tumor cancers.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Parent Company
Primary Office
  • 2400 Broadway
  • Santa Monica, CA 90404
  • United States
+1 (310) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Kite Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 03-Oct-2017 $12B 00000 0000 Completed Profitable
4. Secondary Transaction - Open Market 01-Apr-2015 00000 Completed Generating Revenue
3. IPO 20-Jun-2014 00000 00000 00000 Completed Generating Revenue
2. Mezzanine 28-Apr-2014 $50M $85M Completed Clinical Trials - Phase 2
1. Early Stage VC (Series A) 15-May-2013 $35M $35M 00000 Completed Clinical Trials - Phase 2
To view Kite Pharma’s complete valuation and funding history, request access »

Kite Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view Kite Pharma’s complete cap table history, request access »

Kite Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of active immunotherapies for cancer intended to cure cancer. The company is engaged in developing engineered
Biotechnology
Santa Monica, CA
200 As of 2022
00000
000 0000-00-00
000000&0 00000

00000000

labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris n
0000000000000
Vancouver, Canada
000 As of 0000
00000
0000 0000-00-00
000000000000

000000

prehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat
0000000000000
Utrecht, Netherlands
00 As of 0000
00.000
0000000000 0 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Kite Pharma Competitors (36)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Zymeworks Formerly VC-backed Vancouver, Canada 000 00000 000000000000
000000 Venture Capital-Backed Utrecht, Netherlands 00 00.000 0000000000 0 00.000
0000000 0000000000 Venture Capital-Backed Philadelphia, PA 00 00000 00000000000 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
000000000 00000000 Corporation Pasadena, CA 000 00.000 000000 - 000 00.000
You’re viewing 5 of 36 competitors. Get the full list »

Kite Pharma Patents

Kite Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210161959-A1 Chimeric antigen receptor t cell therapy Pending 06-Nov-2019 0000000000
US-20200397823-A1 Tgf-beta receptors and methods of use Pending 21-Jun-2019 0000000000
AU-2020267378-A1 Methods of administering chimeric antigen receptor immunotherapy Pending 03-May-2019 000000000
CA-3138707-A1 Methods of administering chimeric antigen receptor immunotherapy Pending 03-May-2019 000000000
US-20200384027-A1 Methods of administering chimeric antigen receptor immunotherapy Pending 03-May-2019 A61K35/17
To view Kite Pharma’s complete patent history, request access »

Kite Pharma Executive Team (23)

Name Title Board Seat Contact Info
Francesco Marincola MD Executive, Research & Global Head of Cell Therapy Research
Johanna McLoughlin Chief Financial Officer
Chuck Calderaro Senior Vice President and Global Head of Technical Operations.
Prentice Curry Senior Vice President, Quality and Compliance
Mert Aktar Vice President and Head of Corporate Development
You’re viewing 5 of 23 executive team members. Get the full list »

Kite Pharma Board Members (9)

Name Representing Role Since
Christi Shaw Self Chief Executive Officer & Board Member 000 0000
Roy Doumani Kite Pharma Independent Director 000 0000
You’re viewing 2 of 9 board members. Get the full list »

Kite Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kite Pharma Former Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Alta Partners Venture Capital Minority 000 0000 000000 0
Arie Belldegrun Angel (individual) Minority 000 0000 000000 0
BB Biotech Asset Manager Minority 000 0000 000000 0
Bellco Capital Family Office Minority 000 0000 000000 0
Commercial Street Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 13 investors. Get the full list »

Kite Pharma Investments & Acquisitions (9)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 000 02-Nov-2021 00000 0000 00000 Drug Discovery
0000 00000000 24-Feb-2021 00000 0000 0000 Drug Delivery 000000000
000000000 000 16-Feb-2021 00000 0000 0000 Drug Discovery
0000000 00000 28-Aug-2019 00000 0000 0000 Drug Discovery
Gadeta 19-Jul-2018 Early Stage VC Biotechnology
You’re viewing 5 of 9 investments and acquisitions. Get the full list »